Real-world costs of autosomal dominant polycystic kidney disease in the Nordics

• Main Authors: Daniel Eriksson (Author), Linda Karlsson (Author), Oskar Eklund (Author), Hans Dieperink (Author), Eero Honkanen (Author), Jan Melin (Author), Kristian Selvig (Author), Johan Lundberg (Author)
• Format: Book
• Published: BMC, 2017-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.1186/s12913-017-2513-8; 1472-6963
• Keywords: Polycystic kidney diseases; ADPKD; Health Care Costs; Health Expenditures; Cost of Illness; Public aspects of medicine; RA1-1270
• Source: BMC Health Services Research, Vol 17, Iss 1, Pp 1-9 (2017)

Abstract Background There is limited real-world data on the economic burden of patients with autosomal dominant polycystic kidney disease (ADPKD). The objective of this study was to estimate the annual direct and indirect costs of patients with ADPKD by severity of the disease: chronic kidney disease (CKD) stages 1-3; CKD stages 4-5; transplant recipients; and maintenance dialysis patients. Methods A retrospective study of ADPKD patients was undertaken April-December 2014 in Denmark, Finland, Norway and Sweden. Data on medical resource utilisation were extracted from medical charts and patients were asked to complete a self-administered questionnaire. Results A total of 266 patients were contacted, 243 (91%) of whom provided consent to participate in the study. Results showed that the economic burden of ADPKD was substantial at all levels of the disease. Lost wages due to reduced productivity were large in absolute terms across all disease strata. Mean total annual costs were highest in dialysis patients, driven by maintenance dialysis care, while the use of immunosuppressants was the main cost component for transplant care. Costs were twice as high in patients with CKD stages 4-5 compared to CKD stages 1-3. Conclusions Costs associated with ADPKD are significant and the progression of the disease is associated with an increased frequency and intensity of medical resource utilisation. Interventions that can slow the progression of the disease have the potential to lead to substantial reductions in costs for the treatment of ADPKD.